Syndax Pharmaceuticals (NASDAQ:SNDX) Announces Quarterly Earnings Results, Misses Expectations By $0.79 EPS

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.79), Zacks reports.

Syndax Pharmaceuticals Stock Down 1.0 %

SNDX stock traded down $0.16 during mid-day trading on Monday, hitting $15.48. The company had a trading volume of 3,144,761 shares, compared to its average volume of 2,292,709. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -4.26 and a beta of 0.90. The company has a 50-day moving average price of $14.19 and a 200 day moving average price of $16.78. Syndax Pharmaceuticals has a 12-month low of $12.06 and a 12-month high of $25.16.

Insider Transactions at Syndax Pharmaceuticals

In related news, CEO Michael A. Metzger sold 13,288 shares of the business's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the sale, the chief executive officer now owns 300,121 shares in the company, valued at approximately $4,651,875.50. The trade was a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Keith A. Goldan sold 3,777 shares of the company's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $58,543.50. Following the sale, the chief financial officer now directly owns 90,746 shares in the company, valued at approximately $1,406,563. The trade was a 4.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 21,683 shares of company stock valued at $336,087. 4.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on SNDX. StockNews.com downgraded Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, November 23rd. Citigroup boosted their target price on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a "buy" rating in a research report on Tuesday, November 19th. HC Wainwright reiterated a "buy" rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 10th. Scotiabank decreased their target price on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a report on Wednesday, January 8th. Finally, The Goldman Sachs Group boosted their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a "buy" rating in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $36.20.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).